TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21749847

Group type: EXPERIMENTAL
Intervention: Midodrine plus standard medical therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard medical therapy alone
Number of subjects: 40
Study: 20632084

Group type: EXPERIMENTAL
Intervention: Fulvestrant 250 mg/month (approved dose)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Fulvestrant 250 mg plus loading dose (500 mg on day 0, 250 mg on days 14, 28, and monthly thereafter)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Fulvestrant 500 mg (high dose)
Number of subjects: 144
Study: 17156264

Group type: EXPERIMENTAL
Intervention: Individualized multimedia computer program for health education (n = 33)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Health education by a physician (n = 32)
Number of subjects: 65
Study: 16192581

Group type: EXPERIMENTAL
Intervention: Paroxetine 10 mg
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 12474951

Group type: EXPERIMENTAL
Intervention: Cavities prepared by Er:YAG laser irradiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cavities prepared by air-turbine
Number of subjects: 0
Study: 10548902

Group type: EXPERIMENTAL
Intervention: Orlistat 3 x 120 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8527701

Group type: EXPERIMENTAL
Intervention: Roxatidine acetate 150 mg
Number of subjects: 84

Group type: COMPARATOR
Intervention: Ranitidine 300 mg
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Roxatidine acetate
Number of subjects: 84
Study: 2337212

Group type: EXPERIMENTAL
Intervention: 0.2 or 0.3 mg/kg diltiazem 60 seconds before laryngoscopy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 20
Study: 372027

Group type: EXPERIMENTAL
Intervention: Betamethasone valerate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Halcinonide
Number of subjects: 0
Study: 31034561

Group type: EXPERIMENTAL
Intervention: Basivertebral nerve (BVN) radiofrequency ablation, n=27 (decreased opioid use)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Sham control, n=19 (decreased opioid use)
Number of subjects: 69
Study: 30721963

Group type: EXPERIMENTAL
Intervention: Fat-free mass
Number of subjects: 487404

Group type: EXPERIMENTAL
Intervention: Fat mass
Number of subjects: 487404

Group type: EXPERIMENTAL
Intervention: Fat-free mass (causal effect)
Number of subjects: 487404

Group type: EXPERIMENTAL
Intervention: Fat mass (causal effect)
Number of subjects: 487404

Group type: EXPERIMENTAL
Intervention: Fat-free mass (multivariate MR)
Number of subjects: 487404

Group type: EXPERIMENTAL
Intervention: Fat mass (multivariate MR)
Number of subjects: 487404
Study: 28033561

Group type: EXPERIMENTAL
Intervention: Aspirin (10 days of intake)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Aspirin resistance tests (PFA‐200, VerifyNow®, TXB2)
Number of subjects: 48
Study: 26273264

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX), amoxicillin (AMX) 500 mg, metronidazole (MET) 250 mg
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 24107737

Group type: EXPERIMENTAL
Intervention: LCI699 (aldosterone synthase inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LCI699
Number of subjects: 0
Study: 21435642

Group type: EXPERIMENTAL
Intervention: Oral tramadol
Number of subjects: 120

Group type: COMPARATOR
Intervention: Oral naproxen
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Administration at fixed intervals
Number of subjects: 120

Group type: COMPARATOR
Intervention: Pain scores
Number of subjects: 120
Study: 19643125

Group type: EXPERIMENTAL
Intervention: Educational intervention with Coping Skills Training (CST) and health coaching
Number of subjects: 198

Group type: COMPARATOR
Intervention: Educational intervention without CST and health coaching (Control)
Number of subjects: 198
Study: 17825135

Group type: EXPERIMENTAL
Intervention: Rectal misoprostol 800 microg
Number of subjects: 450

Group type: COMPARATOR
Intervention: Intramuscular oxytocin 10 IU
Number of subjects: 450
Study: 15086765

Group type: EXPERIMENTAL
Intervention: Keratinocyte monolayers on collagen pads (group 1)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Keratinocyte-microbeads (group 2)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Multiple applications of keratinocyte-microbeads (group 3)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Comparison between group 1 and group 3
Number of subjects: 15
Study: 11575533

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.5% lidocaine
Number of subjects: 20
Study: 9781859

Group type: EXPERIMENTAL
Intervention: Cerana inlays with a polyacid‐modified composite
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cerana inlays with a highly viscous luting composite
Number of subjects: 60

Group type: COMPARATOR
Intervention: Empress inlays with a highly viscous luting composite
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cerana inlays with a low‐viscous luting composite
Number of subjects: 60
Study: 7884018

Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLU)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Imipramine (IMI)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Both FLU and IMI
Number of subjects: 124
Study: 6147866

Group type: EXPERIMENTAL
Intervention: Flurazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Temazepam
Number of subjects: 0
Study: 31183514

Group type: EXPERIMENTAL
Intervention: Pertuzumab 840 mg intravenous plus trastuzumab and chemotherapy
Number of subjects: 374

Group type: COMPARATOR
Intervention: Placebo plus trastuzumab and chemotherapy
Number of subjects: 374
Study: 30285835

Group type: EXPERIMENTAL
Intervention: Care informed by results of an additional placental factor blood test
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 0
Study: 26691769

Group type: EXPERIMENTAL
Intervention: Protein supplementation (PRO group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (CON group)
Number of subjects: 20
Study: 22529036

Group type: EXPERIMENTAL
Intervention: Neurobehavioral intervention (n = 25), weekly sessions
Number of subjects: 38

Group type: COMPARATOR
Intervention: Usual care (n = 13), standard weekly home visits
Number of subjects: 38
Study: 23128439

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Carbamazepine (CBZ)
Number of subjects: 128
Study: 20973982

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa 300 μg Q2W or 500 μg Q3W (EDS)
Number of subjects: 752

Group type: COMPARATOR
Intervention: Darbepoetin alfa 150 μg QW (weekly)
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (both groups)
Number of subjects: 752

Group type: COMPARATOR
Intervention: Darbepoetin alfa (QW group)
Number of subjects: 752
Study: 17589695

Group type: EXPERIMENTAL
Intervention: Hybrid material contact lens (DK 23)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Rigid-gas-permeable contact lens (DK 30)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both lens types
Number of subjects: 22
Study: 17362430

Group type: EXPERIMENTAL
Intervention: Clinically depressed patients
Number of subjects: 114

Group type: COMPARATOR
Intervention: Normal matched subjects
Number of subjects: 114
Study: 14702424

Group type: EXPERIMENTAL
Intervention: On-pump surgery
Number of subjects: 104

Group type: COMPARATOR
Intervention: Off-pump surgery
Number of subjects: 104
Study: 11049920

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sufentanil
Number of subjects: 30
Study: 10323115

Group type: EXPERIMENTAL
Intervention: Tenoxicam 40 mg intravenous injection at induction, followed by 20 mg tablet in the evening of the operation and 20 mg daily from days 2 to 7
Number of subjects: 35

Group type: COMPARATOR
Intervention: Diclofenac sodium 75 mg intramuscular injection at induction, followed by 50 mg tablet 4 to 6 hours after operation and 50 mg three times daily for the next 6 days
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Tenoxicam group
Number of subjects: 35
Study: 1728160

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 20
Study: 2858187

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Doxepin
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 504

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 504
Study: 31683159

Group type: EXPERIMENTAL
Intervention: 50% height starting position
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 36" starting position
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: bi-acromial distance starting position
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: bi-acromial distance with reach to 36" starting position
Number of subjects: 34
Study: 31293262

Group type: EXPERIMENTAL
Intervention: Dyract (compomer)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Freedom (compomer)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Equia (high‐viscosity glass ionomer cement)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fuji IX (resin‐modified glass ionomer cement)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ketac Molar (traditional glass ionomer cement)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Voco (traditional glass ionomer cement)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fluoride release analysis
Number of subjects: 30
Study: 28604089

Group type: EXPERIMENTAL
Intervention: 0.9 mL of 2% lidocaine with epinephrine 1:100,000
Number of subjects: 160

Group type: COMPARATOR
Intervention: 0.9 mL of 4% articaine with epinephrine 1:100,000
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Both groups (lidocaine and articaine)
Number of subjects: 160
Study: 26493267

Group type: EXPERIMENTAL
Intervention: Paclitaxel and Carboplatin intercalated with Gefitinib (PCG) - P 175 mg/m², C AUC 5 on day 1, G 250 mg orally on days 2-15 for four cycles followed by G 250 mg orally until progressive disease.
Number of subjects: 90

Group type: COMPARATOR
Intervention: Paclitaxel and Carboplatin alone (PC) - same dosing schedule for four cycles only.
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Paclitaxel and Carboplatin intercalated with Gefitinib (PCG)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Paclitaxel and Carboplatin alone (PC)
Number of subjects: 90
Study: 22427403

Group type: EXPERIMENTAL
Intervention: Nefopam
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 21170558

Group type: EXPERIMENTAL
Intervention: 2.5-cm mesial resection
Number of subjects: 207

Group type: COMPARATOR
Intervention: 3.5-cm mesial resection
Number of subjects: 207
Study: 19491536

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 4400
Study: 17336941

Group type: EXPERIMENTAL
Intervention: Naltrexone 100 mg/day
Number of subjects: 92

Group type: COMPARATOR
Intervention: Naltrexone 0 mg/day (placebo)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Naltrexone 50 mg/day
Number of subjects: 92
Study: 14763917

Group type: EXPERIMENTAL
Intervention: Bariatric surgery (significant weight loss)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Diet (small weight loss)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Obese patients (no intervention)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Obese patients with T2DM
Number of subjects: 96
Study: 11248662

Group type: EXPERIMENTAL
Intervention: Clodronate 800 mg daily by mouth
Number of subjects: 677

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 677
Study: 8996143

Group type: COMPARATOR
Intervention: Cisplatin 75 mg/m2 every 3 weeks plus Cyclophosphamide 750 mg/m2 (CC group, n = 22)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Cisplatin 75 mg/m2 every 3 weeks plus Paclitaxel 175 mg/m2 over a 3-hour infusion (CP group, n = 24)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Cisplatin plus Cyclophosphamide (CC group)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Cisplatin plus Paclitaxel (CP group)
Number of subjects: 46
Study: 8490639

Group type: EXPERIMENTAL
Intervention: Experimental healthy weight regulation curriculum
Number of subjects: 967

Group type: COMPARATOR
Intervention: No-treatment control classes
Number of subjects: 967
Study: 3449047

Group type: EXPERIMENTAL
Intervention: Full-time care in the special nursing home unit
Number of subjects: 0

Group type: COMPARATOR
Intervention: Community care (waiting list with periodic respite care)
Number of subjects: 0
Study: 29642382

Group type: EXPERIMENTAL
Intervention: Low glycaemic index dietary intervention during pregnancy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no specific dietary advice)
Number of subjects: 60
Study: 27194175

Group type: EXPERIMENTAL
Intervention: Virtual clinic
Number of subjects: 208

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 208
Study: 24864486

Group type: EXPERIMENTAL
Intervention: sylvinite speleoclimatotherapy (10 sessions, 60 min each) in addition to conventional pharmacotherapy
Number of subjects: 23

Group type: COMPARATOR
Intervention: traditional medicamental therapy alone
Number of subjects: 23
Study: 23402084

Group type: COMPARATOR
Intervention: TAC-Placebo (PLAC)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: TAC-Short-term (2 mo) low-dose steroid (STER)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Composite endpoint
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Rejection treatment
Number of subjects: 35
Study: 20377585

Group type: EXPERIMENTAL
Intervention: ADA + C/B
Number of subjects: 730

Group type: COMPARATOR
Intervention: ADA + vehicle
Number of subjects: 730
Study: 18534177

Group type: EXPERIMENTAL
Intervention: Low-fluoride dentifrice without post-brushing rinse
Number of subjects: 5

Group type: COMPARATOR
Intervention: Conventional fluoride dentifrice followed by a water rinse
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Low-fluoride dentifrice with post-brushing rinse
Number of subjects: 5
Study: 16248241

Group type: EXPERIMENTAL
Intervention: Modified Qingwen Baidu Decoction (MQBD) in addition to conventional therapy (corticosteroid, anti-viral, anti-bacterial, symptomatic and supporting therapy)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional therapy (corticosteroid, anti-viral, anti-bacterial, symptomatic and supporting therapy)
Number of subjects: 34
Study: 12503692

Group type: EXPERIMENTAL
Intervention: salmeterol (50 microg b.d.; SM50)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: fluticasone propionate (250 microg b.d.; FP250)
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 9794674

Group type: EXPERIMENTAL
Intervention: Oral misoprostol 200 microg
Number of subjects: 178

Group type: COMPARATOR
Intervention: Intravaginal misoprostol 50 microg
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 178
Study: 7636057

Group type: EXPERIMENTAL
Intervention: Inhaled furosemide (10 mg/body square meters)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (0.9% saline solution)
Number of subjects: 40
Study: 2696034

Group type: EXPERIMENTAL
Intervention: Treatment arm 1
Number of subjects: 762

Group type: COMPARATOR
Intervention: Treatment arm 2
Number of subjects: 762
Study: 335867

Group type: EXPERIMENTAL
Intervention: Trimazosin (300 and 450 mg daily)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Trimazosin
Number of subjects: 16
Study: 31272711

Group type: EXPERIMENTAL
Intervention: Spinal manipulation thrusts of perceived least intensity
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Spinal manipulation thrusts of perceived appropriate intensity
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Spinal manipulation thrusts of perceived greatest intensity
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Low pressure models
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Thrust duration and time to peak acceleration
Number of subjects: 13
Study: 28699044

Group type: EXPERIMENTAL
Intervention: UVA1 phototherapy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Narrowband UVB (NB‐UVB) therapy
Number of subjects: 64
Study: 25500679

Group type: EXPERIMENTAL
Intervention: TIVA (propofol-remifentanil total i.v. anaesthesia)
Number of subjects: 80

Group type: COMPARATOR
Intervention: DES (desflurane anaesthesia)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: TIVA
Number of subjects: 80

Group type: COMPARATOR
Intervention: DES
Number of subjects: 80
Study: 23827983

Group type: EXPERIMENTAL
Intervention: Wii-balance board intervention (6 weeks, M=8h, 22 min, SD=53 min)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 29
Study: 20495919

Group type: EXPERIMENTAL
Intervention: Standard dose capecitabine (CCB 1) 1,250 mg/m² p.o. twice daily for 2 weeks
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Dose-intensified capecitabine (CCB 2) 1,750 mg/m² p.o. twice daily for 1 week
Number of subjects: 7
Study: 19335850

Group type: EXPERIMENTAL
Intervention: RV apical pacing
Number of subjects: 800

Group type: COMPARATOR
Intervention: RV septal pacing
Number of subjects: 800
Study: 16400045

Group type: EXPERIMENTAL
Intervention: Accumulating ten 3‐min bouts of exercise (totaling 30 minutes)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: One continuous 30‐min bout of exercise
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control trial (no exercise)
Number of subjects: 10
Study: 15385204

Group type: EXPERIMENTAL
Intervention: Intravascular sonotherapy (IST)
Number of subjects: 403

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 403
Study: 11296045

Group type: EXPERIMENTAL
Intervention: Oral tramadol
Number of subjects: 64

Group type: COMPARATOR
Intervention: Oral diclofenac
Number of subjects: 64
Study: 9370898

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 25 mg/m2
Number of subjects: 26

Group type: COMPARATOR
Intervention: Hydrocortisone 15 mg/m2
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Fludrocortisone
Number of subjects: 26
Study: 1555625

Group type: EXPERIMENTAL
Intervention: SR-verapamil 360 mg o.d.
Number of subjects: 19

Group type: COMPARATOR
Intervention: nifedipine 20 mg t.d.s.
Number of subjects: 19
Study: 3890279

Group type: EXPERIMENTAL
Intervention: Prostacyclin
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 30676426

Group type: EXPERIMENTAL
Intervention: Traditional dysphagia therapy
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: rTMS
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Combined intervention (rTMS + traditional dysphagia therapy)
Number of subjects: 18
Study: 28807635

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg (n=183)
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg with laser (n=180)
Number of subjects: 455

Group type: COMPARATOR
Intervention: Laser (with optional ranibizumab 0.5 mg after month 6; n=92)
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg with laser
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg monotherapy
Number of subjects: 455

Group type: COMPARATOR
Intervention: Laser (monotherapy and combined with ranibizumab from month 6)
Number of subjects: 455
Study: 26318715

Group type: EXPERIMENTAL
Intervention: RV3-BB vaccine (neonatal schedule)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: RV3-BB vaccine (infant schedule)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: RV3-BB vaccine and Placebo
Number of subjects: 95
Study: 23099622

Group type: EXPERIMENTAL
Intervention: Marcy repair
Number of subjects: 91

Group type: COMPARATOR
Intervention: Prolene Hernia System repair
Number of subjects: 91
Study: 20461382

Group type: EXPERIMENTAL
Intervention: PX-12 (54 or 128 mg/m²) administered by 3-hour IV infusion daily for 5 days every 21 days
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: PX-12 (128 mg/m²)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: PX-12 (54 mg/m²)
Number of subjects: 17
Study: 18752112

Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy (CBT)
Number of subjects: 432
Study: 17153908

Group type: EXPERIMENTAL
Intervention: Combined-modality therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care for locally advanced cervical cancer
Number of subjects: 0
Study: 12843799

Group type: EXPERIMENTAL
Intervention: Interferon-gamma (100 MIU subcutaneously)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Granulocyte-macrophage colony-stimulating factor (500 microg subcutaneously)
Number of subjects: 98
Study: 11007235

Group type: EXPERIMENTAL
Intervention: Commercial kit for antitissue transglutaminase antibodies (INOVA Diagnostics, Inc.)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Antiendomysial antibody
Number of subjects: 79

Group type: COMPARATOR
Intervention: Antitissue transglutaminase antibodies (blind determination)
Number of subjects: 79
Study: 8770996

Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclosporine (treatment duration > or = 24 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclosporine (GFR < or = 50 ml/min/1.73 m2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FK‐506
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclosporine to FK‐506 conversion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclosporine and FK‐506
Number of subjects: 0
Study: 1478285

Group type: EXPERIMENTAL
Intervention: Regional isolated perfusion as adjuvant treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Local excision only
Number of subjects: 0
Study: 6494011

Group type: EXPERIMENTAL
Intervention: Polymorphonuclear leukocyte transfusions
Number of subjects: 13

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 13
Study: 3531255

Group type: EXPERIMENTAL
Intervention: Continued UVB phototherapy after initial clearing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Discontinued UVB phototherapy within 3 weeks after initial clearing
Number of subjects: 0
Study: 31453489

Group type: EXPERIMENTAL
Intervention: Physical therapy group (n=52)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (n=52)
Number of subjects: 104
Study: 28318860

Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Fascia Iliaca Compartment Block (FICB)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Retrospective Control Group
Number of subjects: 79